Article

Quetiapine XR: current status for the treatment of major depressive disorder.

Department of Psychiatry, Bucheon St. Mary's Hospital, The Catholic University of Korea College of Medicine, 2 Sosa-Dong, Wonmi-Gu, Pucheon, Kyounggi-Do 420-717, Republic of Korea.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (impact factor: 3.25). 03/2010; 34(7):1165-73. DOI:10.1016/j.pnpbp.2010.03.023 pp.1165-73
Source: PubMed

ABSTRACT Quetiapine fumarate extended release (XR) has been approved for treatment of schizophrenia and bipolar disorder. Quetiapine may have antidepressant effects through effects on 5-HT(2A) receptor, 5-HT(1A) receptor, dopamine receptor, glutamate receptor and norepinephrine transporter. Recently, 7 large-scale randomized, double-blind, placebo (2-studies with active comparator)-controlled clinical trials have demonstrated that quetiapine XR has clinically meaningful efficacy as monotherapy and adjunct therapy to antidepressants for the treatment of adult patients with major depressive disorder (MDD). In such clinical trials, quetiapine XR was generally well tolerated, although weight gain and changes in metabolic parameters, consistent with the known profile of quetiapine, were observed in some patients. As of December 2009, the United States Food and Drug Administration has approved quetiapine XR for the adjunct treatment of MDD. From the data of currently available clinical trials, this review provides an overview of the data and clinical implications for quetiapine XR in the treatment of MDD to enhance clinicians understanding of the use of quetiapine XR in the treatment of MDD.

0 0
 · 
0 Bookmarks
 · 
38 Views
  • Source
    Article: Antidepressant prescribing patterns in Korea: results from the clinical research center for depression study.
    Kyung-Yeol Bae, Sung-Wan Kim, Jae-Min Kim, Il-Seon Shin, Jin-Sang Yoon, Sung-Won Jung, Min-Soo Lee, Hyeon-Woo Yim, Tae-Youn Jun
    [show abstract] [hide abstract]
    ABSTRACT: This study aimed to investigate antidepressant prescribing patterns, including initial choice, switching and combining, and concomitant use of non-antidepressant agents, for depressive disorders in naturalistic clinical care settings in Korea. Patients with depressive disorder were recruited from both outpatient and inpatient settings in 18 hospitals from all over Korea. Treatment was performed in naturalistic patterns based on each clinician's decision. Data were collected on the prescription of antidepressants and concomitant agents from baseline to 12-week follow-up. Selective serotonin reuptake inhibitors (SSRIs) were the most commonly prescribed initial antidepressant (48.9%), followed by newer dual-action antidepressants (45.8%). When an SSRI was the initial antidepressant, 46.2% of patients whose medication was changed were moved to newer dual-action antidepressants, and 67.4% of combination cases were combined with newer dual-action ones. When a newer dual-action antidepressant was the initial antidepressant, 70.6% of patients whose medication was changed were moved to SSRIs, and other antidepressants including tricyclic antidepressants were most commonly added for combination treatment (50% of combination cases). During the treatment period, 20.6% of antidepressants prescribed were augmented by non-antidepressant agents, and 75.1% were used concomitantly with anxiolytics or hypnotics. The most commonly used concomitant non-antidepressant agent was quetiapine. The selection of antidepressants and the concomitant use of non-antidepressant agents are becoming increasingly diversified, and the results of this study reflect changes in the prescribing pattern in actual Korean practices.
    Psychiatry investigation 09/2011; 8(3):234-44. · 0.99 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

2-studies
 
7 large-scale randomized
 
active comparator)-controlled clinical trials
 
adjunct treatment
 
available clinical trials
 
bipolar disorder
 
clinical implications
 
clinical trials
 
clinicians understanding
 
glutamate receptor
 
MDD
 
metabolic parameters
 
overview
 
Quetiapine
 
Quetiapine fumarate
 
quetiapine XR
 
schizophrenia
 
United States Food
 
weight gain
 
XR
 

Chi-Un Pae